Literature DB >> 1929245

Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration.

A R Beaubien1, E Ormsby, A Bayne, K Carrier, G Crossfield, M Downes, R Henri, M Hodgen.   

Abstract

Previous studies have failed to fully establish whether ototoxicity is related in any way to the levels of an aminoglycoside antibiotic in the perilymph. To study this we exposed guinea pigs to continuously infused amikacin at four different dosing rates under conditions parallel to those used in our previous study which related ototoxicity to total plasma area under the concentration-time curve regardless of the level in plasma. It was found that at all dosing rates, levels in the perilymph and ratios of levels in perilymph/plasma remained constant as the dosing duration increased from nonototoxic to strongly ototoxic. Plasma and perilymph amikacin levels were found to be linear functions of the dosing rate even at ototoxic dosing exposures, and ratios of levels in perilymph/plasma did not differ between dosing rates. The total perilymph area under the concentration-time curve was not different between dosing rates either for a total dose associated with threshold ototoxicity or for one associated with severe ototoxicity. The results suggest that amikacin ototoxicity is related to the integral of the concentration in the perilymph over the total time of amikacin exposure regardless of the level in the perilymph.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929245      PMCID: PMC284288          DOI: 10.1128/AAC.35.6.1070

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Distribution of gentamicin by immunofluorescence in the guinea pig inner ear.

Authors:  T Hayashida; Y Nomura; M Iwamori; Y Nagai; T Kurata
Journal:  Arch Otorhinolaryngol       Date:  1985

2.  Gentamicin and verapamil compete for a common transport mechanism in renal brush border membrane vesicles.

Authors:  P P Sokol; K R Huiatt; P D Holohan; C R Ross
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

3.  Effect of pentobarbital anesthesia on amikacin concentrations in plasma and perilymph and evaluation of multiple sampling in perilymph of guinea pigs.

Authors:  S Desjardins-Giasson; A R Beaubien; M J Cauchy
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

4.  Inhibitory effects of gentamicin and ethacrynic acid on mammalian microsomal protein synthesis.

Authors:  W C Buss; R Kauten; M K Piatt
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

5.  Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells.

Authors:  S E Williams; H P Zenner; J Schacht
Journal:  Hear Res       Date:  1987       Impact factor: 3.208

6.  Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels.

Authors:  A R Beaubien; S Desjardins; E Ormsby; A Bayne; K Carrier; M J Cauchy; R Henri; M Hodgen; J Salley; A St Pierre
Journal:  Am J Otolaryngol       Date:  1989 Jul-Aug       Impact factor: 1.808

7.  Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs.

Authors:  P Tran Ba Huy; P Bernard; J Schacht
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  Correlation of amikacin concentrations in perilymph and plasma of continuously infused guinea pigs.

Authors:  S Desjardins-Giasson; A R Beaubien
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Individual variation and mechanism of kanamycin ototoxicity in rabbits.

Authors:  I Ohtani; K Ohtsuki; T Aikawa; T Omata; J Ouchi; T Saito
Journal:  Acta Otolaryngol       Date:  1982 Nov-Dec       Impact factor: 1.494

10.  Inhibition of inner ear ornithine decarboxylase by neomycin in-vitro.

Authors:  C M Henley; H J Gerhardt; J Schacht
Journal:  Brain Res Bull       Date:  1987-12       Impact factor: 4.077

View more
  14 in total

1.  Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

Authors:  P J Wood; L L Ioannides-Demos; E B Bastone; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonates.

Authors:  Yee Shan Low; Sin Li Tan; Angeline Sl Wan
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

3.  Finding ways to solve or prevent aminoglycoside-induced ototoxicity?

Authors:  Jin Li; Connie W Woo
Journal:  Ann Transl Med       Date:  2016-12

Review 4.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  Shripada C Rao; Ravisha Srinivasjois; Kwi Moon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

5.  Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.

Authors:  Ami F Mohamed; Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

6.  Determination of the optimum timing for pharmacokinetic monitoring of once daily aminoglycoside dosing.

Authors:  G Brown; J P McCormack
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 7.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

8.  Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered.

Authors:  Anne Veinstein; Nicolas Venisse; Julie Badin; Michel Pinsard; René Robert; Antoine Dupuis
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Uptake of fluorescent gentamicin by vertebrate sensory cells in vivo.

Authors:  C F Dai; D Mangiardi; D A Cotanche; P S Steyger
Journal:  Hear Res       Date:  2006-02-08       Impact factor: 3.208

Review 10.  Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Authors:  Gary L Darmstadt; Mary Miller-Bell; Maneesh Batra; Paul Law; Kiely Law
Journal:  J Health Popul Nutr       Date:  2008-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.